If you have IgA nephropathy (IgAN), you’ve likely heard about the importance of protecting your kidneys and slowing down the disease. In IgAN, immunoglobulin A (IgA) antibodies accumulate in the ...

Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.

SGLT2 inhibitors curb the action of a protein known as sodium-glucose cotransporter 2, which helps the kidneys reabsorb glucose from the blood. EMPACT-MI is the first analysis to determine if it is ...

ABU DHABI, United Arab Emirates — Whether a newer class of drugs, the sodium glucose cotransporter 2 (SGLT2) inhibitors, should now be considered as first-line therapy in patients with type 2 diabetes ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

A fast-aging fish is giving scientists a rare, accelerated look at how kidneys grow old—and how a common drug may slow that ...

Patients with type 2 diabetes (T2D) who initiated SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection (UTI) had lower risks for mortality, kidney complications, and ...